<DOC>
	<DOCNO>NCT01471535</DOCNO>
	<brief_summary>Hepatitis B surface antigen loss/seroconversion , consider ideal outcome chronic hepatitis B virus ( HBV ) infection , occur spontaneously low rate inactive carrier . The researcher aim investigate ability peginterferon alpha-2a achieve surface antigen loss/seroconversion therapy inactive carrier persistently normal alanine aminotransferase ( ALT ) level , undetectable HBV DNA low surface antigen level , would generally consider candidate therapy .</brief_summary>
	<brief_title>HBsAg Clearance Inactive Chronic HBsAg Carriers After Interferon Treated</brief_title>
	<detailed_description>Chronic HBV inactive carrier enrol out-patient department Beijing Ditan Hospital . All HBsAg positive anti-HBs negative 6 month persistent undetectable HBV DNA normal ALT level measure 3-6 monthly interval precede 2 year well serum HBsAg level ≤100 IU/mL determine two occasion month prior treatment . All patient liver disease contraindication interferon therapy . After give informed consent , patient treat weekly subcutaneous injection peginterferon alpha-2a 180 µg . The use immune suppressive regulatory drug antiviral drug prohibit course study . In study , parameter assess treatment response HBsAg level change . Treatment endpoint HBsAg loss ( ＜0.05 IU/mL ) anti-HBs positive ( ＞10 mIU/mL ) define seroconversion . Depending decline HBsAg level , treatment either continue prolonged period endpoint achieve , terminate case nonresponse . Treatment proceed HBsAg level continue decline HBsAg seroconversion achieve anti-HBs level 200 mIU/ml . If patient willing extend treatment , therapy end time HBsAg loss , stop without decline HBsAg level three month treatment . Liver function parameter , include ALT , aspartate aminotransferase ( AST ) , albumin ( ALB ) total bilirubin ( Tbil ) examine use automated biochemical analyzer . Peripheral blood neutrophil platelet count detect treatment , monitor treatment one three month interval , base test result adjust next checking time . Quantitative HBV DNA test conduct use commercially available real-time fluorescence quantitative PCR kit . HBsAg level quantify Architect i2000 HBsAg quantitative assay ( Abbott Laboratories ) kit . The main efficacy endpoint HBsAg loss seroconversion .</detailed_description>
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis A</mesh_term>
	<mesh_term>Hepatitis , Chronic</mesh_term>
	<mesh_term>Hepatitis B</mesh_term>
	<mesh_term>Hepatitis B , Chronic</mesh_term>
	<mesh_term>Interferons</mesh_term>
	<mesh_term>Interferon-alpha</mesh_term>
	<mesh_term>Peginterferon alfa-2a</mesh_term>
	<criteria>HBsAg positive antiHBs negative 6 month HBeAgnegative/antiHBepositive Persistently undetectable HBV DNA normal ALT level , establish 36 monthly interval precede 2 yrs Serum HBsAg level ≤100 IU/mL , determine two occasion month prior treatment Absence previous antiviral therapy With active alcohol and/or drug consumption With human immunodeficiency virus hepatitis C virus coinfections With clinical evidence cirrhosis With history autoimmune hepatitis With hematological psychiatric disease With evidence neoplastic disease With severe cardiac pulmonary disease</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>March 2015</verification_date>
	<keyword>chronic hepatitis B</keyword>
</DOC>